J&J Posts 9-Cent Q3 EPS, Far Below Prior-Year Levels
JNJ sits 44% above its 52-week low of $184.66.
Summary
Johnson & Johnson reported third-quarter EPS of 9 cents, down from $2.12 a year earlier, on sales of $25.4 billion, with net income of $210 million. Adjusted EPS was $2.59, down 7.5% from the prior year and from $2.90 in Q2. The quarter reflects a one-time special charge of $5.5 billion pretax for the proposed talc litigation resolution, the acquisition of Firefly Bio, and a strategic collaboration with Sail Biomedicines. Innovative Medicine operational sales grew 7.9%, with divestitures negatively affecting growth by 10 basis points, driven primarily by Tremfya, Darzalex, Carvykti, Tecvayli, Rybrevant/Lazcluze, Erleada, Caplyta, and Spravato. The company raised its 2026 adjusted EPS guidance to $11.05-$11.15 from $10.96-$11.11.
Updated with a Dow Jones Newswires report · What changed
Updates
· Dow Jones Newswires — The talc litigation charge totaled $5.5 billion pretax for the quarter.
- Q3 EPS of 9 cents
- Q3 EPS of $2.12 a year earlier
- Adjusted EPS down 7.5% from the prior year
At the time of this announcement, JNJ was trading at $266.55 on NYSE in the Life Sciences sector, with a market capitalization of approximately $635.6B. The 52-week trading range was $184.66 to $281.07. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.